Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2011

01.01.2011 | Retinal Disorders

The effect of laser unit on photodynamic therapy spot size

verfasst von: Siamak Ansari-Shahrezaei, Susanne Binder, Michael Stur

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

To determine the effect of the laser unit on photodynamic therapy (PDT) spot size.

Methods

A calibrated Gullstrand-type model eye was used for this study. The axial length of the model eye was set to different values ranging from 22.2 to 27.0 mm, and the actual spot size from the laser console was recorded for treating a spot of 4 mm in the center of the artificial fundus using two different laser units (Coherent Opal laser; Coherent Inc, Santa Clara, California, USA and Zeiss Visulas laser; Carl Zeiss Meditec Inc, Dublin, California, USA) and two indirect contact laser lenses (Volk PDT laser lens and Volk Area Centralis lens; Volk Optical Inc, Mentor, Ohio, USA).

Results

From myopia to hyperopia, the total deviation from the intended spot size was –22.5% to –7.5% (Opal laser and PDT laser lens), and –17.5% to +2.5% (Visulas laser and PDT laser lens), –12.5% to +7.5% (Opal laser and Area Centralis lens), and –7.5% to +10% (Visulas laser and Area Centralis lens).

Conclusions

The used laser unit has a significant effect on PDT spot size in this model. These findings may be important for optimizing PDT of choroidal neovascular lesions.
Literatur
1.
Zurück zum Zitat Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol 119:198–207 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol 119:198–207
2.
Zurück zum Zitat Verteporfin in Photodynamic Therapy (VIP) Study Group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3. Ophthalmology 110:667–673CrossRef Verteporfin in Photodynamic Therapy (VIP) Study Group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3. Ophthalmology 110:667–673CrossRef
3.
Zurück zum Zitat Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMed Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMed
4.
Zurück zum Zitat Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803–808CrossRefPubMed Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803–808CrossRefPubMed
5.
Zurück zum Zitat Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331PubMed Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331PubMed
6.
Zurück zum Zitat Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroid in the Cynomolgus Monkey. Ophthalmology 106:1915–1923CrossRefPubMed Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroid in the Cynomolgus Monkey. Ophthalmology 106:1915–1923CrossRefPubMed
7.
Zurück zum Zitat Ranchod TM, Brucker AJ, Liu C, Cukras CA, Hopkins TB, Ying GS (2009) Evaluation of actual vs expected photodynamic therapy spot size. Am J Ophthalmol 147:859–864CrossRefPubMed Ranchod TM, Brucker AJ, Liu C, Cukras CA, Hopkins TB, Ying GS (2009) Evaluation of actual vs expected photodynamic therapy spot size. Am J Ophthalmol 147:859–864CrossRefPubMed
8.
Zurück zum Zitat Kondo M, Ito Y, Miyata K, Kondo N, Ishikawa K, Terasaki H (2006) Effect of axial length on laser spot size during photodynamic therapy: an experimental study in monkeys. Am J Ophthalmol 141:214–215CrossRefPubMed Kondo M, Ito Y, Miyata K, Kondo N, Ishikawa K, Terasaki H (2006) Effect of axial length on laser spot size during photodynamic therapy: an experimental study in monkeys. Am J Ophthalmol 141:214–215CrossRefPubMed
9.
Zurück zum Zitat Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of axial length on photodynamic therapy. Am J Ophthalmol 141:699–702CrossRefPubMed Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of axial length on photodynamic therapy. Am J Ophthalmol 141:699–702CrossRefPubMed
10.
Zurück zum Zitat Rassow B (1972) A model of Gullstrand’s normal eye (in German). Ophthalmologica 164:143–148CrossRefPubMed Rassow B (1972) A model of Gullstrand’s normal eye (in German). Ophthalmologica 164:143–148CrossRefPubMed
11.
Zurück zum Zitat Altman DG, Bland JM (1983) Measurement in medicine: the analysis of method comparison studies. Statistician 32:307–317CrossRef Altman DG, Bland JM (1983) Measurement in medicine: the analysis of method comparison studies. Statistician 32:307–317CrossRef
12.
Zurück zum Zitat Antoszyk AN, Tuomi L, Chung CY, Singh A, Focus Study Group (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (Focus): year 2 results. Am J Ophthalmol 145:862–874CrossRefPubMed Antoszyk AN, Tuomi L, Chung CY, Singh A, Focus Study Group (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (Focus): year 2 results. Am J Ophthalmol 145:862–874CrossRefPubMed
13.
Zurück zum Zitat Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O (2006) Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 113:2243–2250CrossRefPubMed Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O (2006) Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 113:2243–2250CrossRefPubMed
14.
Zurück zum Zitat Tao Y, Jonas JB (2010) Refractive error and smoking habits in exudative age-related macular degeneration in a hospital-based setting. Eye 24:648–652CrossRefPubMed Tao Y, Jonas JB (2010) Refractive error and smoking habits in exudative age-related macular degeneration in a hospital-based setting. Eye 24:648–652CrossRefPubMed
15.
Zurück zum Zitat Ulvik SO, Seland JH, Wentzel-Larsen T (2005) Refraction, axial length and age-related maculopathy. Acta Ophthalmol Scand 83:419–423 Ulvik SO, Seland JH, Wentzel-Larsen T (2005) Refraction, axial length and age-related maculopathy. Acta Ophthalmol Scand 83:419–423
16.
Zurück zum Zitat Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of digital measurement software on photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:137–142CrossRefPubMed Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of digital measurement software on photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:137–142CrossRefPubMed
17.
Zurück zum Zitat Stur M, Ansari-Shahrezaei S (2001) The effect of axial length on laser spot size and laser irradiance. Arch Ophthalmol 119:1323–1328PubMed Stur M, Ansari-Shahrezaei S (2001) The effect of axial length on laser spot size and laser irradiance. Arch Ophthalmol 119:1323–1328PubMed
18.
Zurück zum Zitat Ansari-Shahrezaei S, Ergun E, Stur M (2006) Digital area measurement of fundus landmarks. Graefes Arch Clin Exp Ophthalmol 244:649–653CrossRefPubMed Ansari-Shahrezaei S, Ergun E, Stur M (2006) Digital area measurement of fundus landmarks. Graefes Arch Clin Exp Ophthalmol 244:649–653CrossRefPubMed
19.
Zurück zum Zitat Ansari-Shahrezaei S, Ergun E, Chong R, Tufail A, Wedrich A, Stur M (2007) Magnification-corrected photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 245:333–337CrossRefPubMed Ansari-Shahrezaei S, Ergun E, Chong R, Tufail A, Wedrich A, Stur M (2007) Magnification-corrected photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 245:333–337CrossRefPubMed
20.
Zurück zum Zitat Bennett AG, Rudnicka AR, Edgar DF (1994) Improvements on Littmann’s method of determining the size of retinal features by fundus photography. Graefes Arch Clin Exp Ophthalmol 232:361–367CrossRefPubMed Bennett AG, Rudnicka AR, Edgar DF (1994) Improvements on Littmann’s method of determining the size of retinal features by fundus photography. Graefes Arch Clin Exp Ophthalmol 232:361–367CrossRefPubMed
Metadaten
Titel
The effect of laser unit on photodynamic therapy spot size
verfasst von
Siamak Ansari-Shahrezaei
Susanne Binder
Michael Stur
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2011
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-010-1460-4

Weitere Artikel der Ausgabe 1/2011

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2011 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.